Dimerix receives US$10 million upfront payment from Everest under DMX-200 licensing agreement
- nuaxia
- il y a 20 heures
- 3 min de lecture
The payment strengthens Dimerix's balance sheet while advancing its regional partnering strategy for the Phase III kidney disease therapy DMX-200 across Asia.
Dimerix has received the US$10 million upfront payment from Everest Medicines under their previously announced exclusive licensing agreement covering DMX-200 for all indications, including focal segmental glomerulosclerosis (FSGS), across Greater China, South Korea and selected Southeast Asian markets.
The payment reinforces Dimerix's non-dilutive funding strategy while supporting continued development of DMX-200 and expanding the company's global commercialisation network through regional licensing partnerships.
Field | Content |
Alert Type | Deal |
Companies | Dimerix Limited; Everest Medicines |
Deal Type | Licensing agreement (upfront payment under previously announced exclusive regional licence) |
Asset or Company | DMX-200 |
Therapy Area(s) | Nephrology; Rare Kidney Diseases |
Technology or Modality | Small-molecule CCR2 inhibitor |
Deal Value | US$10 million upfront payment (approximately A$14.1 million) received. Dimerix remains eligible for up to a further US$330 million in development, regulatory and commercial milestone payments, plus 10–15% tiered royalties on net sales. The milestone payments are contingent and are not guaranteed. (Announcements ASX) |
Development Stage | Phase III (ACTION3 trial for focal segmental glomerulosclerosis) (Announcements ASX) |
Geography | Greater China, South Korea and selected Southeast Asian countries |
What Happened | On 20 August 2026, Dimerix announced receipt of the US$10 million upfront payment from Everest Medicines under the exclusive licensing agreement announced in June 2026. Everest holds exclusive rights to develop and commercialise DMX-200 across all indications in Greater China, South Korea and selected Southeast Asian markets, while Dimerix continues to lead and fund the global Phase III ACTION3 study. Everest is responsible for regulatory submissions and commercialisation activities within the licensed territories. (Announcements ASX) |
Why It Matters | The payment provides additional non-dilutive funding as Dimerix advances DMX-200 through Phase III development while validating its strategy of securing regional commercial partners rather than retaining worldwide commercial rights. Everest also brings established expertise in nephrology and commercial infrastructure across key Asian markets. (Announcements ASX) |
Supporting Context | Everest is Dimerix's fifth regional licensing partner for DMX-200, following agreements with Advanz Pharma, Taiba Rare, Fuso Pharmaceutical Industries and BioMarin (following its acquisition of Amicus' rights). Across these five partnerships, Dimerix has received more than A$80 million in upfront payments and is eligible for approximately A$1.9 billion in potential milestone payments, excluding royalties. (Announcements ASX) |
Strategic Rationale | Dimerix secures non-dilutive capital while retaining rights in unlicensed territories and leveraging regional partners for commercial execution. Everest expands its nephrology portfolio with a late-stage rare kidney disease programme that complements its existing capabilities in the region. (Announcements ASX) |
Potential Impact | If DMX-200 achieves regulatory approval, Dimerix could generate significant milestone and royalty income while accelerating patient access through established regional partners. The commercial outcome remains dependent on successful completion of the ACTION3 Phase III trial and subsequent regulatory approvals. (Announcements ASX) |
Key Takeaway | Receipt of the US$10 million upfront payment reinforces Dimerix's regional licensing strategy while providing additional funding to advance its Phase III kidney disease programme. (Announcements ASX) |
What to Watch | Completion of the ACTION3 Phase III trial, potential achievement of development milestones triggering further payments, and additional regional licensing agreements for territories that remain unpartnered. (Announcements ASX) |
Primary Source | |
Relevant Date | 20 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires